Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.

Moehler, M; Mahlberg, R; Heinemann, V; Obermannová, R; Kubala, E; Melichar, B; Weinmann, A; Scigalla, P; Tesařová, M; Janda, P; Hédouin-Biville, F; Mansoor, Was

dc.contributor.author	Moehler, M
dc.contributor.author	Mahlberg, R
dc.contributor.author	Heinemann, V
dc.contributor.author	Obermannová, R
dc.contributor.author	Kubala, E
dc.contributor.author	Melichar, B
dc.contributor.author	Weinmann, A
dc.contributor.author	Scigalla, P
dc.contributor.author	Tesařová, M
dc.contributor.author	Janda, P
dc.contributor.author	Hédouin-Biville, F
dc.contributor.author	Mansoor, Was
dc.date.accessioned	2016-08-10T10:05:49Z
dc.date.available	2016-08-10T10:05:49Z
dc.date.issued	2016-06-02
dc.identifier.citation	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. 2016: Gastric Cancer	en
dc.identifier.issn	1436-3305
dc.identifier.pmid	27255289
dc.identifier.doi	10.1007/s10120-016-0618-0
dc.identifier.uri	http://hdl.handle.net/10541/618170
dc.description.abstract	This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).
dc.language	ENG
dc.language.iso	en	en
dc.rights	Archived with thanks to Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	en
dc.title	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.	en
dc.type	Article	en
dc.contributor.department	Medizinische Klinik und Poliklinik, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany	en
dc.identifier.journal	Gastric Cancer	en
refterms.dateFOA	2020-06-18T14:44:47Z
html.description.abstract	This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).